Anaphylaxis to insect stings

Immunology and Allergy Clinics of North America

Volumn 35, Issue 2, 2015, Pages 287-302

  Golden, David B K ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Anaphylaxis; Diagnostic tests; Hymenoptera; Immunotherapy; Insect sting; Mastocytosis; Venom

Indexed keywords

ADRENALIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G; INSECT VENOM; TRYPTASE;

ANAPHYLAXIS; CLINICAL FEATURE; CROSS REACTION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; EPINEPHRINE AUTOINJECTOR; HUMAN; HYMENOPTERA; HYPOTENSION; IMMUNOTHERAPY; INJECTION SITE REACTION; INSECT ALLERGY; INSECT STING; MASTOCYTOSIS; MEDICAL HISTORY; PATHOPHYSIOLOGY; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; SKIN TEST; SYSTEMIC DISEASE; VENOM IMMUNOTHERAPY; ANIMAL; IMMUNOLOGY; INSECT BITE; RISK FACTOR;

ANAPHYLAXIS; ANIMALS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOGLOBULIN E; INSECT BITES AND STINGS; RISK FACTORS;

EID: 84926419304     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2015.01.007     Document Type: Review

References (89)

1. Graft D.F., Schuberth K.C., Kagey-Sobotka A., et al. AProspective study of the natural history of large local reactions following Hymenoptera stings in children. JPediatr 1984, 104:664-668.
2. Hogendijk S., Hauser C. Wasp sting-associated cold urticaria. Allergy 1997, 52:1145-1146.
3. Wong C.C., Borici-Mazi R. Delayed-onset cold anaphylaxis after Hymenoptera sting. Ann Allergy Asthma Immunol 2012, 109:77-78.
4. Reisman R.E. Unusual reactions to insect stings. Curr Opin Allergy Clin Immunol 2005, 5:355-358.
5. Triggiani M., Patella V., Staiano R.I., et al. Allergy and the cardiovascular system. Clin Exp Immunol 2008, 153(Suppl 1):7-11.
6. Muller U.R. Cardiovascular disease and anaphylaxis. Curr Opin Allergy Clin Immunol 2007, 7:337-341.
7. Pucci S., Antonicelli L., Bilo M.B., et al. The short interval between two stings as a risk factor for developing Hymenoptera venom allergy. Allergy 1994, 49:894-896.
8. Stoevesandt J., Hain J., Kerstan A., et al. Over- and underestimated parameters in severe Hymenoptera venom-induced anaphylaxis: cardiovascular medication and absence of urticaria/angioedema. JAllergy Clin Immunol 2012, 130:698-704.
9. Lockey R.F., Turkeltaub P.C., Baird-Warren I.A., et al. The Hymenoptera venom study. I. 1979-1982: demographic and history-sting data. JAllergy Clin Immunol 1988, 82:370-381.
10. Barnard J.H. Studies of 400 Hymenoptera sting deaths in the United States. JAllergy Clin Immunol 1973, 52:259-264.
11. Schuberth K.C., Lichtenstein L.M., Kagey-Sobotka A., et al. An epidemiologic study of insect allergy in children. I. Characteristics of the disease. JPediatr 1982, 100:546-551.
12. Insect Allergy Committee, American Academy of Allergy Insect sting allergy, cooperative study. JAMA 1965, 193:115-120.
13. Alvarez-Twose I., Gonzalez-de-Olano D., Sanchez-Munoz L., et al. Clinical, biological and molecular characteristics of systemic mast cell disorders presenting with severe mediator-related symptoms. JAllergy Clin Immunol 2010, 125:1269-1278.
14. Golden D.B., Breisch N.L., Hamilton R.G., et al. Clinical and entomological factors influence the outcome of sting challenge studies. JAllergy Clin Immunol 2006, 117:670-675.
15. Kemp S.F., deShazo R.D., Moffitt J.E., et al. Expanding habitat of the imported fire ant: a public health concern. JAllergy Clin Immunol 2000, 105:683-691.
16. Tracy J.M., Demain J.G., Quinn J.M., et al. The natural history of exposure to the imported fire ant. JAllergy Clin Immunol 1995, 95:824-828.
17. Shek L.P., Ngiam N.S., Lee B.W. Ant allergy in Asia and Australia. Curr Opin Allergy Clin Immunol 2004, 4:325-328.
18. Hoffman D.R. Hymenoptera venoms: composition, standardization, stability. Monograph on insect allergy 2004, 37-53. American Academy of Allergy Asthma and Immunology, Milwaukee (WI). 4th edition. M.I. Levine, R.F. Lockey (Eds.).
19. King T.P., Spangfort M.D. Structure and biology of stinging insect venom allergens. Int Arch Allergy Immunol 2000, 123:99-106.
20. Hemmer W., Frocke M., Kolarich K., et al. Antibody binding to venom carbohydrates is a frequent cause for double positivity to honeybee and yellow jacket venom in patients with stinging insect allergy. JAllergy Clin Immunol 2001, 108:1045-1052.
21. Hoffman D.R., Jacobson R.S., Schmidt M., et al. Allergens in Hymenoptera venoms. XXIII. Venom content of imported fire ant whole body extracts. Ann Allergy 1991, 66:29-31.
22. Freeman T.M., Hyghlander R., Ortiz A., et al. Imported fire ant immunotherapy: effectiveness of whole body extracts. JAllergy Clin Immunol 1992, 90:210-215.
23. Steigelman D.A., Freeman T.M. Imported fire ant allergy: case presentation and review of incidence, prevalence, diagnosis and current treatment. Ann Allergy Asthma Immunol 2013, 111:242-245.
24. Bilo B.M., Bonifazi F. Epidemiology of insect-venom anaphylaxis. Curr Opin Allergy Clin Immunol 2008, 8:330-337.
25. Golden D.B., Marsh D.G., Kagey-Sobotka A., et al. Epidemiology of insect venom sensitivity. JAMA 1989, 262:240-244.
26. Graft D.F. Insect sting allergy. Med Clin North Am 2006, 90:211-232.
27. Hoffman D.R. Fatal reactions to Hymenoptera stings. Allergy Asthma Proc 2003, 24:123-127.
28. Schwartz H.J., Sutheimer C., Gauerke B., et al. Venom-specific IgE antibodies in postmortem sera from victims of sudden unexpected death. JAllergy Clin Immunol 1984, 73:189. [abstract].
29. Sturm G.J., Kranzelbinder B., Schuster C., et al. Sensitization to Hymenoptera venoms is common, but systemic sting reactions are rare. JAllergy Clin Immunol 2014, 133:1635-1643.e1.
30. Golden D.B., Marsh D.G., Freidhoff L.R., et al. Natural history of Hymenoptera venom sensitivity in adults. JAllergy Clin Immunol 1997, 100:760-766.
31. Valentine M.D., Schuberth K.C., Kagey-Sobotka A., et al. The value of immunotherapy with venom in children with allergy to insect stings. NEngl J Med 1990, 323:1601-1603.
32. Golden D.B., Kagey-Sobotka A., Norman P.S., et al. Outcomes of allergy to insect stings in children with and without venom immunotherapy. NEngl J Med 2004, 351:668-674.
33. Hoffman D.R., Jacobson R.S. Allergens in Hymenoptera venom. XII. How much protein is in a sting?. Ann Allergy 1984, 52:276-278.
34. vanderLinden P.G., Hack C.E., Struyvenberg A., et al. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis. JAllergy Clin Immunol 1994, 94:151-159.
35. Golden D.B., Langlois J., Valentine M.D. Treatment failures with whole body extract therapy of insect sting allergy. JAMA 1981, 246:2460-2463.
36. Golden D.B., Moffitt J., Nicklas R.A., American Academy of Allergy, Asthma & Immunology (AAAAI) Stinging insect hypersensitivity: a practice parameter update 2011. JAllergy Clin Immunol 2011, 127:852-854.
37. Golden D.B. Advances in diagnosis and management of insect sting allergy. Ann Allergy Asthma Immunol 2013, 111:84-89.
38. Goldberg A., Confino-Cohen R. Timing of venom skin tests and IgE determinations after insect sting anaphylaxis. JAllergy Clin Immunol 1997, 100:183-184.
39. Graif Y., Confino-Cohen R., Goldberg A. Reproducibility of skin testing and serum venom-specific IgE in Hymenoptera venom allergy. Ann Allergy 2006, 96:24-29.
40. Reisman R.E. Intentional diagnostic insect sting challenges: a medical and ethical issue. JAllergy Clin Immunol 1993, 91:1100. [letter].
41. Rueff F., Przybilla B., Muller U., et al. The sting challenge test in Hymenoptera venom allergy. Allergy 1996, 51:216-225.
42. Franken H.H., Dubois A.E., Minkema H.J., et al. Lack of reproducibility of a single negative sting challenge response in the assessment of anaphylactic risk in patients with suspected yellow jacket hypersensitivity. JAllergy Clin Immunol 1994, 93:431-436.
43. Eberlein B., Krischan L., Darsow U., et al. Double positivity to bee and wasp venom: improved diagnostic procedure by recombinant allergen-based IgE testing and basophil activation test including data about cross-reactive carbohydrate determinants. JAllergy Clin Immunol 2012, 130:155-161.
44. Muller U.R., Johansen N., Petersen A.B., et al. Hymenoptera venom allergy: analysis of double positivity to honey bee and Vespula venom by estimation of IgE antibodies to species-specific major allergens Api m1 and Ves v5. Allergy 2009, 64:543-548.
45. Muller U.R., Schmid-Grendelmeier P., Hausmann O., et al. IgE to recombinant allergens Api m 1, Ves v 1, and Ves v 5 distinguish double sensitization from crossreaction in venom allergy. Allergy 2012, 67:1069-1073.
46. Eberlein-Konig B., Schmidt-Leidescher C., Behrendt H., et al. Predicting side-effects in venom immunotherapy by basophil activation?. Allergy 2006, 61:897.
47. Kucera P., Cvackova M., Hulikova K., et al. Basophil activation can predict clinical sensitivity in patients after venom immunotherapy. JInvestig Allergol Clin Immunol 2010, 20:110-116.
48. Zitnik S.E., Vesel T., Avcin T., et al. Monitoring honeybee venom immunotherapy in children with the basophil activation test. Pediatr Allergy Immunol 2012, 23:166-172.
49. Rueff F., Przybilla B., Bilo M.B., et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase - a study of the EAACI Interest Group on Insect Venom Hypersensitivity. JAllergy Clin Immunol 2009, 124:1047-1054.
50. Niedoszytko M., deMonchy J., vanDoormaal J.J., et al. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009, 64:1237-1245.
51. Bonadonna P., Perbellini O., Passalacqua G., et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. JAllergy Clin Immunol 2009, 123:680-686.
52. Haeberli G., Bronnimann M., Hunziker T., et al. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003, 33:1216-1220.
53. Kucharewicz I., Bodzenta-Lukaszyk A., Szymanski W., et al. Basal serum tryptase level correlates with severity of Hymenoptera sting and age. JInvestig Allergol Clin Immunol 2007, 17:65-69.
54. Muller U.R. Elevated baseline serum tryptase, mastocytosis and anaphylaxis. Clin Exp Allergy 2009, 39:620-622.
55. Rueff F., Przybilla B., Bilo M.B., et al. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. JAllergy Clin Immunol 2010, 126:105-111.
56. Oude-Elberink J., deMonchy J., Kors J., et al. Fatal anaphylaxis after a yellow jacket sting despite venom immunotherapy in two patients with mastocytosis. JAllergy Clin Immunol 1997, 99:153-154.
57. Pravettoni V., Piantanida M., Primavesi L., et al. Basal platelet-activating factor acetylhydrolase: prognostic marker of severe Hymenoptera venom anaphylaxis. JAllergy Clin Immunol 2014, 133:1218-1220.
58. Vadas P., Gold M., Perelman B., et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. NEngl J Med 2008, 358:28-35.
59. Lieberman P., Nicklas R.A., Oppenheimer J., et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. JAllergy Clin Immunol 2010, 126:477-480.
60. Pumphrey R.S. Fatal posture in anaphylactic shock. JAllergy Clin Immunol 2003, 112:451-452.
61. Clark S., Long A.A., Gaeta T.J., et al. Multicenter study of emergency department visits for insect sting allergies. JAllergy Clin Immunol 2005, 116:643-649.
62. Oude-Elberink J.N., deMonchy J.G., vanderHeide S., et al. Venom immunotherapy improves health-related quality of life in yellow jacketallergic patients. JAllergy Clin Immunol 2002, 110:174-182.
63. Oude-Elberink J.N., vanderHeide S., Guyatt G.H., et al. Analysis of the burden of treatment in patients receiving an Epi-Pen for yellow jacket anaphylaxis. JAllergy Clin Immunol 2006, 118:699-704.
64. Oude-Elberink J.N., vanderHeide S., Guyatt G.H., et al. Immunotherapy improves health-related quality of life in adult patients with dermal reactions following yellow jacket stings. Clin Exp Allergy 2009, 39:883-889.
65. Hunt K.J., Valentine M.D., Sobotka A.K., et al. Acontrolled trial of immunotherapy in insect hypersensitivity. NEngl J Med 1978, 299:157-161.
66. Reisman R.E. Natural history of insect sting allergy: relationship of severity of symptoms of initial sting anaphylaxis to re-sting reactions. JAllergy Clin Immunol 1992, 90:335-339.
67. Mauriello P.M., Barde S.H., Georgitis J.W., et al. Natural history of large local reactions from stinging insects. JAllergy Clin Immunol 1984, 74:494-498.
68. Bernstein J.A., Kagan S.L., Bernstein D.I., et al. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy 1994, 73:423-428.
69. Birnbaum J., Charpin D., Vervloet D. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy 1993, 23:226-230.
70. Tankersley M.S., Walker R.L., Butler W.K., et al. Safety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment. JAllergy Clin Immunol 2002, 109:556-562.
71. Brown S.G., Wiese M.D., vanEeden P., et al. Ultrarush versus semirush initiation of insect venom immunotherapy: a randomized controlled trial. JAllergy Clin Immunol 2012, 130:162-168.
72. Brown S.G., Wiese M.D., Blackman K.E., et al. Ant venom immunotherapy: a double-blind placebo-controlled crossover trial. Lancet 2003, 361:1001-1006.
73. Lockey R.F., Turkeltaub P.C., Olive E.S., et al. The Hymenoptera venom study III: safety of venom immunotherapy. JAllergy Clin Immunol 1990, 86:775-780.
74. Mosbech H., Muller U. Side effects of insect venom immunotherapy: results from an EAACI study. Allergy 2000, 55:1005-1010.
75. Muller U.R., Jutel M., Reimers A., et al. Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. JAllergy Clin Immunol 2008, 122:1001-1007.
76. Wohrl S., Gamper S., Hemmer W., et al. Premedication with montelukast reduces large local reactions of allergen immunotherapy. Int Arch Allergy Immunol 2007, 144:137-142.
77. Golden D.B., Lawrence I.D., Kagey-Sobotka A., et al. Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. JAllergy Clin Immunol 1992, 90:386-393.
78. Varga E.M., Francis J.N., Zach M.S., et al. Time course of serum inhibitory activity for facilitated allergen-IgE binding during bee venom immunotherapy in children. Clin Exp Allergy 2009, 39:1353-1357.
79. Dreschler K., Bratke K., Petermann S., et al. Impact of immunotherapy on blood dendritic cells in patients with Hymenoptera venom allergy. JAllergy Clin Immunol 2011, 127:487-494.
80. Ozdemir C., Kucuksezer U.C., Akdis M., et al. Mechanisms of immunotherapy to wasp and bee venom. Clin Exp Allergy 2011, 41:1226-1234.
81. Golden D.B., Kwiterovich K.A., Kagey-Sobotka A., et al. Discontinuing venom immunotherapy: outcome after five years. JAllergy Clin Immunol 1996, 97:579-587.
82. Golden D.B., Kwiterovich K.A., Addison B.A., et al. Discontinuing venom immunotherapy: extended observations. JAllergy Clin Immunol 1998, 101:298-305.
83. Cavalucci E., Ramondo S., Renzetti A., et al. Maintenance venom immunotherapy administered at a 3 month interval preserves safety and efficacy and improves adherence. JInvestig Allergol Clin Immunol 2010, 20:63-68.
84. Muller U., Berchtold E., Helbling A. Honeybee venom allergy: results of a sting challenge 1 year after stopping venom immunotherapy in 86 patients. JAllergy Clin Immunol 1991, 87:702-709.
85. Reisman R.E., Lantner R. Further observations of stopping venom immunotherapy: comparison of patients stopped because of a fall in serum venom-specific IgE to insignificant levels with patients stopped prematurely by self-choice. JAllergy Clin Immunol 1989, 83:1049-1054.
86. Golden D.B., Kagey-Sobotka A., Lichtenstein L.M. Survey of patients after discontinuing venom immunotherapy. JAllergy Clin Immunol 2000, 105:385-390.
87. Lerch E., Muller U. Long-term protection after stopping venom immunotherapy. JAllergy Clin Immunol 1998, 101:606-612.
88. Muller U., Helbling A., Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. JAllergy Clin Immunol 1992, 89:529-535.
89. Reisman R.E. Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis. JAllergy Clin Immunol 1993, 92:831-836.